指南与共识浆细胞疾病

骨髓瘤患者管理中影像学使用指南

Guidelines for the use of imaging in the management of patients with myeloma.
指南 / 共识 · Br J Haematol · 2017-07-05

该指南由Br J Haematol发布,基于证据提出骨髓瘤及浆细胞瘤患者诊断和随访中最新影像学模态的使用与技术应用方法。文中指出国际骨髓瘤工作组(IMWG)已将横断面影像纳入骨髓瘤定义和冒烟型骨髓瘤疾病定义,并用于定义微小残留病阴性新反应类别;国家卫生与临床优化研究所(NICE)骨髓瘤指南也推荐对疑似骨髓瘤患者使用横断面影像。平片曾是初诊检查的标准模态,但CT、MRI和18F-FDG PET/CT等横断面模态证据不断增加,资金和可及性仍是障碍。

要点

  • IMWG修订的骨髓瘤定义将横断面影像作为定义骨病的方法,并纳入疑似冒烟型骨髓瘤的疾病定义。
  • NICE骨髓瘤指南推荐对疑似骨髓瘤患者使用横断面影像。
  • IMWG近期将影像纳入定义微小残留病阴性新反应类别,无论是否有影像学疾病证据。

核心结论

  • 本文提出基于证据的方法,用于骨髓瘤和浆细胞瘤患者诊断及随访中最新影像学模态的使用与技术应用。

研究设计与样本

  • 本文为Br J Haematol发布的指南,制定机构与方法原文未报告。

主要发现

  • IMWG近期修订的骨髓瘤定义包括横断面影像作为定义骨病的方法,并将其纳入疑似冒烟型骨髓瘤患者的疾病定义。
  • NICE骨髓瘤指南推荐对疑似骨髓瘤患者使用横断面影像。
  • IMWG近期将影像纳入定义微小残留病阴性新反应类别,无论是否有基于影像的疾病证据。
  • 平片既往是初诊骨髓瘤检查中纳入的标准影像模态,但CT、MRI和18F-FDG PET/CT等横断面模态的证据不断增加。
  • 较新影像技术的资金及因此的可及性仍是障碍。

关键数值与推荐

  • IMWG修订的骨髓瘤定义将横断面影像作为定义骨病的方法,并纳入疑似冒烟型骨髓瘤的疾病定义。
  • NICE骨髓瘤指南推荐对疑似骨髓瘤患者使用横断面影像。
  • IMWG近期将影像纳入定义微小残留病阴性新反应类别,无论是否有基于影像的疾病证据。

临床怎么用

  • 本文提出基于证据的方法,用于骨髓瘤和浆细胞瘤患者诊断及随访中最新影像学模态的使用与技术应用。

局限性

  • 较新影像技术的资金及因此的可及性仍是障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of imaging in myeloma has gained increasing importance over the past few years. The recently revised definition of myeloma from the International Myeloma Working Group (IMWG) includes cross sectional imaging as a method to define bone disease and also incorporates its use in the disease definition for patients with suspected smouldering myeloma. The National Institute for Health and Care Excellence myeloma guidelines also recommend cross sectional imaging for patients with suspected myeloma. There is also increasing use of imaging in disease assessments and the International Myeloma Working Group has recently incorporated imaging in defining new response categories of minimal residual disease negativity, with or without imaging-based evidence of disease. Plain X-rays have previously been the standard imaging modality included in a myeloma work up at presentation but evidence is mounting for use of cross-sectional modalities such as computed tomography (CT), magnetic resonance imaging (MRI) and 18 fluoro-deoxyglucose (18 F-FDG) positron emission tomography (PET)/CT. Funding and therefore availability of newer imaging techniques remains a barrier. Here, we propose an evidence-based approach to the use and technical application of the latest imaging modalities at diagnosis and in the follow-up of patients with myeloma and plasmacytoma.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chantry A, Kazmi M, Barrington S, et al. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017. PMID: 28677897. doi:10.1111/bjh.14827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。